- Home
- ASG vs TSHA Comparison
ASG vs TSHA Comparison
Compare ASG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASG
- TSHA
- Stock Information
- Founded
- ASG 1986
- TSHA 2019
- Country
- ASG United States
- TSHA United States
- Employees
- ASG N/A
- TSHA N/A
- Industry
- ASG Investment Managers
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- ASG Finance
- TSHA Health Care
- Exchange
- ASG Nasdaq
- TSHA Nasdaq
- Market Cap
- ASG 350.7M
- TSHA 403.7M
- IPO Year
- ASG N/A
- TSHA 2020
- Fundamental
- Price
- ASG $5.70
- TSHA $1.85
- Analyst Decision
- ASG
- TSHA Strong Buy
- Analyst Count
- ASG 0
- TSHA 8
- Target Price
- ASG N/A
- TSHA $6.63
- AVG Volume (30 Days)
- ASG 324.3K
- TSHA 4.9M
- Earning Date
- ASG 01-01-0001
- TSHA 11-13-2024
- Dividend Yield
- ASG 8.09%
- TSHA N/A
- EPS Growth
- ASG N/A
- TSHA N/A
- EPS
- ASG N/A
- TSHA N/A
- Revenue
- ASG N/A
- TSHA $9,915,000.00
- Revenue This Year
- ASG N/A
- TSHA N/A
- Revenue Next Year
- ASG N/A
- TSHA N/A
- P/E Ratio
- ASG N/A
- TSHA N/A
- Revenue Growth
- ASG N/A
- TSHA N/A
- 52 Week Low
- ASG $4.47
- TSHA $1.19
- 52 Week High
- ASG $5.71
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- ASG 42.46
- TSHA 38.54
- Support Level
- ASG $5.82
- TSHA $1.80
- Resistance Level
- ASG $5.87
- TSHA $2.72
- Average True Range (ATR)
- ASG 0.08
- TSHA 0.23
- MACD
- ASG -0.03
- TSHA -0.10
- Stochastic Oscillator
- ASG 33.72
- TSHA 3.81
About ASG Liberty All-Star Growth Fund Inc.
Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.